Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor–Positive Breast Cancers

Abstract

These studies provide preclinical rationale to test CDK4/6i and radiotherapy in women with locally advanced ER⁺ breast cancer at high risk for locoregional recurrence.